May 13, 2022
Article
At a median follow-up of 20.7 months in patients with papillary disease (n = 77), the median DFS was 23.6 months.
April 07, 2022
Article
The applications for germline and somatic genetic testing in prostate cancer have skyrocketed, carving out an important role in screening, diagnosis, and treatment.
February 24, 2022
Article
Despite missing the primary end point, avelumab did demonstrate notable clinical activity and a favorable safety profile in the phase 2 ARIES trial.
February 18, 2022
Article
Findings from the phase 3 MAGNITUDE trial showed that adding niraparib to abiraterone acetate significantly extended radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations.